USA flag logo/image

An Official Website of the United States Government

Lentiviral Vectors for the Treatment of Fanconi Anemia

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2010 / STTR
Agency Tracking Number:
R41HL099150
Solicitation Year:
2010
Solicitation Topic Code:
NHLBI
Solicitation Number:
PA09-114
Small Business Information
RIMEDION, INC.
351 W 10TH ST, STE 514 INDIANAPOLIS, IN 46202-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2010
Title: Lentiviral Vectors for the Treatment of Fanconi Anemia
Agency: HHS
Contract: 1R41HL099150-01
Award Amount: $223,172.00
 

Abstract:

DESCRIPTION (provided by applicant): HIV-1 based lentiviral vectors are becoming an increasingly attractive means of integrating transgenes into target cells. Vectors are in or enterning clinical trials for a diverse group of ailments, including genetic disease, AIDS and cancer. Rimedion and its research partner, Indiana University School of Medicine proposes to develop a novel lentiviral vector for the treatment of Fanconi anemia. While the vector construct will be derived from HIV-1 based lentiviral system, the vector will be pseudotyped with a proprietary viral envelope derived from the human foamy virus. Specific Aim 1: Generate recombinant lentiviral constructs that encode the expression of the FANCA cDNA by the human phosphoglycerate kinase promoter orthe elongation factor 1a promoter and test functional expression of the transgenes in murine Fanca -/- progenitors and human FANCA deficient lymphoblastoid cell lines. Specific Aim 2: Optimize production of a lentiviral vector pseudotyped with a proprietary PFV envelope using GMP complaint methodology. In this Phase I application, the clinical vector construct and optimized production methodology will finalized. In Phase II, Rimedion will generate vector and complete efficacy and toxicity data for inclusion in an IND filing. The work will lead to a Phase I clinical trial using the novel vector to transduce autologous peripheral blood stem cells from Fanconi anemia patients. As discussed in our application, the proof-of-principle has been well established that gene transfer can correct the hematologic defects of this disease, the efficiency of gene transfer using prior vector systems has been the major limitation to developing a commerical product. Rimedion believes the novel vector system described will provide a curative therapy for this genetic disease. PUBLIC HEALTH RELEVANCE: Gene therapy for Fanconi anemia has been successful in murine models but human cures have been limited by the low transduction efficiency of retroviral vectors. Rimedion willutilize a novel lentiviral vector combined with a proprietary foamy virus envelope to improve efficiency and decrease toxicity of gene transfer. Rimedion will optimize the vector and production methods in this application enabling a Phase I clinical trial.

Principal Investigator:

David W. Clapp
317-278-9290
dclapp@iupui.edu

Business Contact:

Butch L. Mercer
317-637-9000
butchmercer@rimedion.com
Small Business Information at Submission:

RIMEDION, INC.
351 W 10TH ST, STE 514 INDIANAPOLIS, IN 46202-

EIN/Tax ID: 126301504
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Research Institution Information:
Indiana University
601 E KIRKWOOD AVE
BLOOMINGTON, IN 47405-1223
Contact: